Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Burkitt Lymphoma 1

Interventions

Rituximab 129Cyclophosphamide 122Doxorubicin 62Vincristine 61venetoclax 58Prednisone 57ibrutinib 52Specimen Handling 50fludarabine 47Lenalidomide 47Biopsy 46obinutuzumab 43acalabrutinib 42Etoposide 41fludarabine phosphate 36Magnetic Resonance Spectroscopy 36Cytarabine 35CT-P10 35Dexamethasone 34Methotrexate 29Bendamustine Hydrochloride 27pembrolizumab 26Nivolumab 22blinatumomab 21zanubrutinib 20prednylidene 19Calcium Dobesilate 19deltacortene 18Radiotherapy 18Melphalan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leyk × Lymphoid × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡